Pricing people out of using Mounjaro would be bad news for the NHS - COMMENT: The astronomical rise in weight-loss drug ...

Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Steroid dealers using social media and beauty salons to sell cheap Chinese copies of weight-loss drugs, experts warn ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...